Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis

Lichtstimulation Zur Verbesserung Der Sehleistung Bei Patientinnen Und Patienten Mit Multipler Sklerose Nach Sehnerventzündung

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The aim of this monocentric randomized controlled intervention study is to improve visual function in persons with multiple sclerosis following optic neuritis (neuritis nervi optici) by means of a light stimulation. In the treatment arm, two 80-second light stimulations are to be administered daily for 12 days in 25 persons with multiple sclerosis following recent optic neuritis (1-3 months). For the standardized application of light stimulation in the sense of standardized training, the light stimulation is to be carried out by watching a generated flicker video on a mobile phone. In a sham-intervened control group (sample size 25), the spontaneous course after optic neuritis will be recorded in parallel. Intensive neuronal stimulation of the visual pathway will be used to stimulate regenerative processes, which will be recorded by means of changes in high-contrast visual acuity (primary endpoint). Secondary endpoints are changes in a colored-contrast test, in 2.5% low contrast visual acuity, the peak conduction latency of visual evoked potentials, and retinal layer thicknesses and vessel densities measured in optical coherence tomography and optical coherence tomorgraphic angiography. These physiological parameters should help to understand the underlying processes of a potentially altered visual performance.

Who May Be Eligible (Plain English)

Who May Qualify: - Relapsing remitting multiple sclerosis or clinically isolated syndrome or no indication of chronic inflammatory central nervous system disease - Age 18-60 years - Optic neuritis within 1-3 months Who Should NOT Join This Trial: - Epilepsy - Light-triggered migraine - Insufficient vision correction - Retinal disease (glaucoma, macular edema, macula degeneration, ...) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Relapsing remitting multiple sclerosis or clinically isolated syndrome or no indication of chronic inflammatory central nervous system disease * Age 18-60 years * Optic neuritis within 1-3 months Exclusion Criteria: * Epilepsy * Light-triggered migraine * Insufficient vision correction * Retinal disease (glaucoma, macular edema, macula degeneration, ...)

Treatments Being Tested

DEVICE

Light stimulation

see arm description

DEVICE

Sham light stimulation

see arm description

Locations (1)

Technical University of Munich
Munich, Bavaria, Germany